CannEconomy cannabis medical marijuana

Ep. 472: Mara Gordon

September 23, 2019

Based on her personal experiences, Mara Gordon, co-founder of Aunt Zelda’s, has become passionate about using cannabis to treat patients with illnesses and injuries. Gordon notes that, based on her data, THC is the most medically useful cannabinoid, although she is also a strong proponent of medical-use CBD. She also points out that, typically, younger patients require higher doses, whereas older patients require lower doses. This could be due to number of cannabinoid receptors, metabolism speed, or mere differences in psychology. Besides science, Gordon believes that products need to be well understood with everything printed on the label.


Seth Adler: Mara Gordon joins us. Welcome to Cannabis Economy. I'm your host Seth Adler. Download episodes on That's two Ns in the word "economy," or wherever you currently get your podcasts. I've got a ton of direct insight from leaders in policy science and business up on, as well as one-on-ones on cannabinoids and 2018 research supplements to the National Academies of Science's Engineering and Medicine Report from 2017. First a word from Wana Brands and then Mara Gordon.
Seth Adler: Want to know with Wana Brands? Nancy, we've been talking about global expansion, and really other industries are starting to realize that cannabis is an industry of innovation.
Nancy: Yes. I think that's going to be one of the major trends that we're going to see over the next couple of years. Somebody said to me recently that we're moving from bro science to grow science, which I love. But I think that we're getting a lot more sophisticated about the plant itself, how to extract, more specifically how to separate the various terpenes and cannabinoids and how to recombine them in different ways. Additionally, you're going to see a lot of people working for different ways to increase bioavailability to make sure that more of the THC and other substances from the plant get into the body efficiently. So I think just in terms of the plant itself, we're seeing a ton of innovation. Then I think we're seeing a lot of innovation from ancillary businesses that support.
Seth Adler: Let's step in the way back machine and really tell the history here so we know what we're dealing with. Then once we have established that, dive in on where we need to be going as far as science. Does that line up as far as a good objective for us?
Mara Gordon: Yes, whatever makes you happy, makes me happy.

Read the full transcript:

Become a member to access to webinars, quarterly reports, contributor columns, shows, excerpts, and complete podcast transcripts

Become a Member

Already a member? Login here.